Acquired by AstraZeneca
On June 10, 2013 AstraZeneca announced they will be entering into a definitive merger agreement with Pearl Therapeutics. AstraZeneca purchased 100% of Pearl Therapeutics shares for up to $1.15 billion.
On October 19, 2010 Pearl Therapeutics completed their series C funding round with $69 million in funding from Vatera Healthcare Partners (lead investor), New Leaf Venture Partners, and 5AM Ventures.
Private equity round
On October 1, 2012 Pearl Therapeutics completed a private equity fundraising round with $23.3 million in funding from Vatera Healthcare Partners, New Leaf Venture Partners, Clarus Ventures, and 5AM Ventures.
On November 13, 2012 Pearl Therapeutics completed their series D funding round with $65 million in funding from Vetera Healthcare Partners (lead investor), New Leaf Venture Partners, Clarus Ventures, and 5AM Ventures.
On April 1, 2013 Pearl Therapeutics completed a venture funding round with $41.7 million in funding from Vatera Healthcare Partners (lead investor), New Leaf Venture Partners, Clarus Ventures, and 5AM Ventures.
Saykon Y. Dee
Vito Isamu Prasad
Documentaries, videos and podcasts
- BiotechnologyBiotechnology can refer to the application of science and technology to living organisms or the use of living organisms, their parts, products or models thereof to solve a problem, produce knowledge or produce goods and services. Biotechnology may involve the alteration of living or non-living materials.